Idioma:

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Sadoff, Jerald ; Gray, Glenda ; Vandebosch, An ; Cárdenas, Vicky ; Shukarev, Georgi ; Grinsztejn, Beatriz ; Goepfert, Paul A ; Truyers, Carla ; Van Dromme, Ilse ; Spiessens, Bart ; Vingerhoets, Johan ; Custers, Jerome ; Scheper, Gert ; Robb, Merlin L ; Treanor, John ; Ryser, Martin F ; Barouch, Dan H ; Swann, Edith ; Marovich, Mary A ; Neuzil, Kathleen M ; Corey, Lawrence ; Stoddard, Jeffrey ; Hardt, Karin ; Ruiz-Guiñazú, Javier ; Le Gars, Mathieu ; Schuitemaker, Hanneke ; Van Hoof, Johan ; Struyf, Frank ; Douoguih, Macaya

The New England journal of medicine, 2022-03, Vol.386 (9), p.847-860 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
Autor: Sadoff, Jerald ; Gray, Glenda ; Vandebosch, An ; Cárdenas, Vicky ; Shukarev, Georgi ; Grinsztejn, Beatriz ; Goepfert, Paul A ; Truyers, Carla ; Van Dromme, Ilse ; Spiessens, Bart ; Vingerhoets, Johan ; Custers, Jerome ; Scheper, Gert ; Robb, Merlin L ; Treanor, John ; Ryser, Martin F ; Barouch, Dan H ; Swann, Edith ; Marovich, Mary A ; Neuzil, Kathleen M ; Corey, Lawrence ; Stoddard, Jeffrey ; Hardt, Karin ; Ruiz-Guiñazú, Javier ; Le Gars, Mathieu ; Schuitemaker, Hanneke ; Van Hoof, Johan ; Struyf, Frank ; Douoguih, Macaya
Assuntos: Ad26COVS1 - adverse effects ; Ad26COVS1 - immunology ; Adolescent ; Adult ; Confidence intervals ; Coronavirus ; Coronaviruses ; COVID-19 ; COVID-19 - epidemiology ; COVID-19 - mortality ; COVID-19 - prevention & control ; COVID-19 vaccines ; Death ; Double-Blind Method ; Follow-Up Studies ; Hospitalization - statistics & numerical data ; Humans ; Immunogenicity, Vaccine ; Infectious Disease ; Kaplan-Meier Estimate ; Middle Aged ; Original ; Patient Acuity ; Placebos ; Population ; Questionnaires ; Safety ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccine efficacy ; Vaccine Efficacy - statistics & numerical data ; Vaccines ; Young Adult
É parte de: The New England journal of medicine, 2022-03, Vol.386 (9), p.847-860
Notas: The members of the ENSEMBLE Study Group are listed in the Supplementary Appendix, available at NEJM.org.
Descrição: The randomized trial assessing the efficacy of a single injection of the Ad26.COV2.S showed 56.3% vaccine efficacy beginning 14 days after injection and 52.9% efficacy more than 28 days after injection against moderate to severe–critical Covid-19. Protection lasted at least 6 months without an added boost. Vaccination was associated with mild-to-moderate adverse effects.
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.